Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 20-week, Randomised, Open-label, 2-armed, Parallel Group Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes Inadequately Controlled With Premixed Human Insulin

NCT01618214 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01618214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01618214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 20-week, Randomised, Open-label, 2-armed, Parallel Group Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes Inadequately Controlled With Premixed Human Insulin
Lead sponsor
Novo Nordisk A/S
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2012
Completion date
January 31, 2013
Enrollment
344 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2